Navigation Links
Therapeutic AIDS vaccine designed by HIVACAT reduces the viral load in the majority of AIDS patients
Date:2/1/2011

The therapeutic vaccines are a priority research line of the HIVACAT, the catalan programme for the development of therapeutic vaccines and prevention against the Human Immunodeficiency Virus (HIV). This type of therapeutic vaccine helps the patients who are carriers of the virus, combat infection and control the appearance of AIDS in the same way as with the current antiretroviral treatments. The final aim of the therapeutic vaccines will be to avoid a life long treatment with antiretroviral drugs. The research team 'Infectious Diseases and AIDS' led by Dr. Josep Maria Gastell from IDIBAPS Hospital Clnic has developed using the brand HIVACAT, a model of the therapuetic vaccine based on the patient's own dendritic cells. This reduction in the viral load is still considered to be insuficient but it is the first therapeutic vaccine which has achieved a postive response in the majority of patients.

The Journal of Infectious Diseases has published the results of this study with Dr. Felipe Garca from the Infectious Diseases Unit of IDIBAPS Hospital Clinic, as first author and Dr. Teresa Gallart from the Immunology Laboratoy of the same centre as last author. The work counted on an international collaboration with teams from France, the Hpital Piti-Salptrire and the Universit Pierre et Marie Curie in Paris/INSERM, and the USA, the National Institute of Cancer in Maryland.

A total of 24 patients participated in this double blind clinical trial, half of whom formed the control Group and who did not receive the vaccine. None of these patients received antiretroviral treatment and to enter into the study had to maintain a good T lymphatic blood load (>450 per mm3). The vaccine was personalized and was made from the dendritic cells of each patient sensitized in the laboratory against an inactive form of their own virus. We are looking at a cell therapy that in the ambit of IDIBAPS received support from the Cell Therapy programme of the University of Barcelona. The vaccine was administered in 3 dosis with an interval of 2 weeks between each one.

At the end of 24 weeks, it showed that the majority of patients had experienced a significant decrease in the viral load. This decrease was very significant is some of them but in no case did the virus become undetectable. However this is a very important improvement with respect to previous initiatives where with a similar vaccine there was a modest response in 30% of the treated patients. No therapeutic vaccine has achieved up to now the same level of response as in this study. A new clinical trial is underway testing the administration of the vaccine in conjunction with antiretroviral drugs to allow an improvement in the results.

The principal objective of therapeutic vaccines is to minimize the need for antiretroviral drug treatment. These treatments have improved enormously over the past few years and have become easy drugs to administer with few side effects. Although the daily administering is not ideal, there is no experience over the long term and it is not known if the treatment could bring about resistance. It aims to deal with the treatment of chronic patients for their whole life which currently is an important economic burden for the health system. The annual budget for antiretrovirals in Hospital Clinic is around 30 Million Euros. Furthermore the therapeutic vaccine is easy to produce and small administrations could be implemented in developing countries, too. To undertake this ambitious objective there has to be a continuing scientific and economic efforts in initiatives such as HIVACAT.


'/>"/>

Contact: Alex Argemi
aargemi@clinic.ub.es
34-932-275-700
IDIBAPS - Institut d'Investigacions Biomdiques August Pi i Sunyer
Source:Eurekalert

Related biology news :

1. Reportlinker Adds Personalized Medicine Market - Advances in Human Genomics and Proteomics to Challenge Traditional Therapeutics
2. SAGE expands Therapeutic Advances series
3. 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
4. FDA Clears Medivances Arctic Sun 5000 for Fastest, Easiest Therapeutic Temperature Management
5. Therapeutic Hypothermia journal launching in spring 2011
6. Discovery opens door to therapeutic development for FSH muscular dystrophy
7. Scripps Research scientists break barrier to creating potential therapeutic molecules
8. Biotherapeutic Innovations on Display at AAPS National Biotechnology Conference
9. Multistage nanovector system provides sustained delivery of siRNA cancer therapeutic in mice
10. AAPS presents therapeutic protein drug interactions workshop
11. Study shows potential for using algae to produce human therapeutic proteins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/21/2016)... , June 21, 2016 NuData ... the new role of principal product architect and ... the director of customer development. Both will report ... technical officer. The moves reflect NuData,s strategic growth ... response to high customer demand and customer focus ...
(Date:6/9/2016)... 2016  Perkotek an innovation leader in attendance control systems is proud to announce ... for employers to make sure the right employees are actually signing in, and to ... ... ... ...
(Date:6/2/2016)... 2, 2016 The Department of Transport ... the 44 million US Dollar project, for the , ... including Personalization, Enrolment, and IT Infrastructure , to ... production and implementation of Identity Management Solutions. Numerous renowned international ... Decatur was selected for the most compliant ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... YORK , June 23, 2016 ... trading session at 4,833.32, down 0.22%; the Dow Jones Industrial ... S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ), ... Therapeutics Inc. (NASDAQ: BIND ). Learn more about ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory ... technical consulting, provides a free webinar on Performing Quality Investigations: Getting ... at 12pm CT at no charge. , Incomplete investigations are still a major ...
(Date:6/23/2016)... , June 22, 2016  Amgen (NASDAQ: ... the QB3@953 life sciences incubator to accelerate ... The shared laboratory space at QB3@953 was created to ... key obstacle for many early stage organizations - access ... the sponsorship, Amgen launched two "Amgen Golden Ticket" awards, ...
(Date:6/22/2016)... , June 22, 2016 Cell ... will allow them to produce up to one ... one lot within one week. These high-quality, consistent ... laboriously preparing cells and spend more time doing ... through a proprietary, high-volume manufacturing process that produces ...
Breaking Biology Technology: